| 論文種別 | 原著(症例報告除く) |
| 言語種別 | 英語 |
| 査読の有無 | その他(不明) |
| 表題 | Prognostic Significance of the BALAD Serological Model in Systemic Therapies for Hepatocellular Carcinoma: A Personalized Approach to the Prediction of Survival Benefit. |
| 掲載誌名 | 正式名：JCO clinical cancer informatics 略 称：JCO Clin Cancer Inform ISSNコード：24734276/24734276 |
| 掲載区分 | 国外 |
| 巻・号・頁 | 9,pp.e2400175 |
| 著者・共著者 | Hidenori Toyoda, Atsushi Hiraoka, Hironori Ochi, Kunihiko Tsuji, Kazuto Tajiri, Joji Tani, Toshifumi Tada, Tomomi Okubo, Masanori Atsukawa, Masashi Hirooka, Ei Itobayashi, Takeshi Hatanaka, Kazuya Kariyama, Toru Ishikawa, Hidekatsu Kuroda, Koichi Takaguchi, Hisashi Kosaka, Kazuhito Kawada, Satoru Kakizaki, Yutaka Yada, Chikara Ogawa, Takashi Nishimura, Satoshi Yasuda, Akihiro Deguchi, Asahiro Morishita, Norio Itokawa, Taeang Arai, Akemi Tsutsui, Atsushi Naganuma, Hirayuki Enomoto, Masaki Kaibori, Kazuhiro Nouso, Yoichi Hiasa, Takashi Kumada, Tomoyuki Akita, Junko Tanaka, Philip J Johnson |
| 発行年月 | 2025/05 |
| 概要 | PURPOSE:The BALAD model, a scoring system for staging hepatocellular carcinoma (HCC), is based on five serum markers: bilirubin, albumin, lens culinaris agglutinin-reactive alpha-fetoprotein [AFP], AFP, and des-gamma-carboxy prothrombin. It has shown good ability to predict survival in patients with HCC irrespective of stage and treatment, a high BALAD value being associated with a poor prognosis. However, its prognostic significance is unclear in patients with advanced unresectable HCC (uHCC) who undergo systemic therapies. We assessed the prognostic ability of BALAD in this subpopulation.METHODS:In a multicenter cohort of 1,510 patients with advanced uHCC treated with first-line systemic therapies, the baseline BALAD score was calculated on the basis of pretreatment serum levels. Overall survival (OS), progression-free survival (PFS), overall response rate (ORR), and disease control rate (DCR) were calculated and related to the BALAD score.RESULTS:In all, 502 patients were treated with sorafenib, 435 with lenvatinib, and 573 with atezolizumab plus bevacizumab. Irrespective of treatment regimen, OS, PFS, ORR, and DCR were all independently negatively correlated with the BALAD score. The beneficial effects of specific systemic therapy regimens differed according to the BALAD score.CONCLUSION:The BALAD score had good prognostic ability for predicting OS and PFS in patients with advanced uHCC who underwent systemic therapies and was associated with treatment response. Application of the BALAD score offers increased precision in the prediction of outcome both for individual patients and for specific subgroups of patients with HCC. |
| DOI | 10.1200/CCI-24-00175 |
| PMID | 40354590 |